您现在的位置: 首页> 研究主题> 尿纤溶酶原激活物

尿纤溶酶原激活物

尿纤溶酶原激活物的相关文献在1994年到2020年内共计328篇,主要集中在内科学、神经病学与精神病学、肿瘤学 等领域,其中期刊论文328篇、专利文献21314篇;相关期刊117种,包括河北中医、实用心脑肺血管病杂志、心血管康复医学杂志等; 尿纤溶酶原激活物的相关文献由1164位作者贡献,包括李天德、杨波、王蓁等。

尿纤溶酶原激活物—发文量

期刊论文>

论文:328 占比:1.52%

专利文献>

论文:21314 占比:98.48%

总计:21642篇

尿纤溶酶原激活物—发文趋势图

尿纤溶酶原激活物

-研究学者

  • 李天德
  • 杨波
  • 王蓁
  • 郑曙民
  • 郭勇峰
  • 关丽娜
  • 刘宗惠
  • 勾俊龙
  • 席刚明
  • 张建林
  • 期刊论文
  • 专利文献

搜索

排序:

年份

    • 李磊; 李会晓
    • 摘要: 目的 探讨急性ST段抬高型心肌梗死(STEMI)选择性冠状动脉内溶栓联合介入治疗与直接冠状动脉内介入治疗的疗效.方法 2018年10月-2019年10月就诊于巩义市人民医院STEMI患者61例,采用随机单盲方法分为对照组(直接PCI)、治疗组(溶栓+PCI),纳入对照组31例,治疗组30例.观察两组冠状动脉血管TIMI血流分级、N末端B型利钠肽原(NT-ProBNP)水平、左心室射血分数(LVEF)值和住院期间病死率、再梗死率、出血事件发生率.结果 治疗后,治疗组TIMI血流分级提高优于对照组(P<0.05).结论 冠状动脉内溶栓后介入治疗对比直接冠状动脉内介入治疗,更能改善患者心肌灌注水平,减少无复流的发生率,且同样能改善心功能和未增加住院期间出血事件的发生率.
    • 曹德茂; 彭爱军; 武永康; 钱程行; 申宝玺; 王友伟; 王鸿生; 齐文涛
    • 摘要: 目的 探讨微创穿刺联合术中尿激酶腔内注射治疗慢性硬膜下血肿的疗效.方法 44例采用微创穿刺技术的慢性硬膜下血肿患者,计算机随机分组,23例穿刺术中注射尿激酶(观察组),21例穿刺术中未注射尿激酶(对照组),对比两组术后次日血肿量变化,统计术后3个月内复发及再手术患者例数,术后3个月Markwalder's分级评估神经功能.结果 观察组及对照组患者性别、年龄及入院时血肿侧、血肿量、血肿厚度、中线偏移以及Markwalder's分级等方面差异均无统计学意义(P>0.05).观察组在术后次日血肿残余量、拔管时间、术后3个月血肿量、复发例数等方面明显优于对照组(P<0.05),再手术例数组间差异无统计学意义(P>0.05).观察组患者术后3个月的Markwalder's分级明显优于对照组(P<0.05);观察组及对照组均未发生再出血及感染等并发症.结论 微创穿刺联合尿激酶术中血肿腔注射治疗慢性硬膜下血肿,操作简易,安全性高,可有效降低血肿残余量,缩短拔除引流管时间,改善患者神经功能,并且降低了复发率,值得临床应用及推广.
    • 陈中美; 张东平; 金鑫
    • 摘要: 目的 探讨尿激酶静脉溶栓治疗高龄急性缺血性脑卒中患者的临床疗效及安全性.方法 选取2013年3月至2017年6月重钢总医院收治的高龄 (80~90岁) 急性缺血性脑卒中患者102例, 其中51例接受尿激酶溶栓及常规治疗 (溶栓组) , 另51例接受常规治疗 (对照组) .分析2组患者治疗前, 治疗后24h、14d及90d的日常生活能力 (ADL) , 以及2组患者24h、14d美国国立卫生研究院卒中量表 (NIHSS) 评分, 观察2组患者不良反应发生情况.结果 溶栓组治疗后24h, 14、90d的ADL评分均明显低于治疗前, 且治疗后14、90d的ADL评分明显低于对照组, 差异均有统计学意义 (P<0.05) .溶栓组治疗后24h、14d的NIHSS评分均明显低于治疗前及对照组治疗后, 差异均有统计学意义 (P<0.05) .溶栓组发生牙龈出血4例 (7.8%) , 穿刺点周围瘀斑3例 (5.9%) , 消化道出血1例 (2.0%) , 缺血性脑卒中出血转化4例 (7.8%) ;对照组发生消化道出血2例 (3.9%) , 缺血性脑卒中出血转化3例 (5.9%) .对症处理后上述症状均消失或改善, 均无死亡病例.结论 尿激酶静脉溶栓治疗高龄急性缺血性脑卒中患者疗效优于常规治疗, 能显著改善日常生活能力、神经功能缺损及预后, 提高患者生活质量.%Objective To investigate the clinical efficacy and safety of intravenous thrombolytic therapy with urokinase in elderly patients with acute ischemic stroke.Methods 102 cases elderly patients (80-90 years old) with acute ischemic stroke in the General Hospital of Chongqing Steel Companyfrom March 2013 to June 2017 were enrolled in the study.Fifty-one cases patients underwent urokinase thrombolysis and conventional therapy (thrombolysis group) , and 51 cases patients received conventional therapy (control group).The ADL before and after treatment at 24 h, 14 dand 90 d, NIHSS scores after treatment at 24 h, 14 d of both groups were analyzed.Complications were observed in 2 groups, and ADL scores were analyzed after 90 days of follow-up.Results Compared with before treatment, the ADL scores of thrombolysis group were significantly decreased at 24 h, 14 dand 90 d after treatment, the differences were statistically significant (P<0.05).Compared with before treatment and control group after treatment, the NIHSS scores of thrombolysis group were significantly decreased at 24 hand 14 dafter treatment, the differences were statistically significant (P<0.05).In the thrombolysis group, there were 4 cases of gingival hemorrhage (7.8%) , 3 cases of puncture site stasis (5.9%) , 1 case of gastrointestinal hemorrhage (2.0%) , and 4 cases of ischemic stroke hemorrhage trasformation (7.8%).In the control group, there were 2 cases of gastrointestinal hemorrhage (3.9%) and 3 cases of ischemic stroke hemorrhage transformation (5.9%).After symptomatic treatment, the above symptoms disappeared or improved, no deaths.ConclusionThe efficacy of intravenous thrombolysis with urokinase in elderly patients with acute ischemic stroke is superior to the conventional therapy, which can significantly improve the daily living ability and neurological function defects, prognosis and quality of life of patients.
    • 周美君; 刘红梅; 严飞; 李素淑
    • 摘要: 目的 构建iRGD靶向载尿激酶脂质体-微泡复合物(iRGD-LMC),探讨其联合超声靶向微泡破坏技术(UTMD)的体外溶栓作用.方法 薄膜-水化法制备靶向微泡,冻融法制备载尿激酶(uPA)脂质体,两者通过生物素-亲和素偶联获得iRGD-LMC.共聚焦显微镜观察其形态特征,颗粒计数仪测定其粒径和浓度,BCA试剂盒测定载药量,Vevo 2100超声成像仪对其进行体外超声成像.设置不同的超声强度及时间,比较药物释放率.制作体外血栓模型,观察iRGD-LMC联合超声的溶栓效果.结果 制备的iRGD-LMC表现为普通微泡形态,浓度为(0.51±0.03)×109/ml,粒径为(2.62±0.12)μm,载药量为每108个复合物载uPA(3878.5±97.8)μg.超声下iRGD-LMC可显影并释放药物.在体外溶栓实验中,iRGD-LMC联合超声组的溶栓效率为(87.66±1.69)%,溶栓效果最好,与阴性对照组 、 单纯超声组 、 单纯尿激酶组 、 单纯iRGD-LMC组比较差异均有统计学意义(P<0.05).结论 成功构建了iRGD-LMC,并结合了脂质体高载药量 、 超声溶栓及微泡助溶的优点.体外实验证实,联合UTMD可促进药物释放,取得了显著的溶栓效果.%Objective To fabricate iRGD targeted liposome-microbubble complex containing uPA ( iRGD-LMC) ,and to improve the thrombolytic efficiency and reduce the risk of thrombolysis by iRGD-LMC combining with ultrasound targeted microbubbles destruction ( UTMD ) to release drug into the thrombus site with the help of microbubble cavitation effect . Methods Biotinylated iRGD-MBs were fabricated by thin-film rehydration method .Biotinylated liposomes containing uPA were fabricated by freeze-thaw method and were conjugated to the biotinylated iRGD-MBs surface through biotin-avidin linkage . The iRGD-LMC was subjected to confocal microscopy to determine the particle morphology . The concentration , average diameter and size distribution were determined by particle sizing instrument . The uPA loading efficiency was measured by BCA Protein Assay Kit . Ultrasound imaging was performed using a Vevo 2100 ultrasound imaging system . The iRGD-LMC was irradiated by different ultrasound time and intensity to release drug . Thrombolytic effect in vitro of iRGD-LMC combined with UTMD was observed on the thrombosis model which was extracted from mouse blood . Results iRGD-LMC was successfully prepared . iRGD-LMC was exhibited a well-defined spherical morphology and homogeneous distribution ,like ordinary microbubbles . The concentration of iRGD-LMC was ( 0 .51 ± 0 .03 ) × 109 / ml and average diameter was ( 2 .62 ± 0 .12) μm . Drugs loading efficiency was ( 3878 .5 ± 97 .8) μg uPA per 108 microbubbles . iRGD-LMC could achieve contrast-enhanced ultrasound imaging in vitro . The thrombolytic effect of iRGD-LMC +US group ( 87 .66 ± 1 .69) % was the best in vitro ,and had significant difference with others groups ( P <0 .05) ,followed by iRGD-LMC group ( 53 .32 ± 4 .86) % and uPA group ( 51 .09 ± 9 .01) % ,Compared with PBS group ,US group ( 23 .56 ± 9 .46) % had thrombolytic effect . Conclusions iRGD-LMC is successfully prepared ,which has the advantages of high drug loading of liposomes and good acoustic properties of microbubbles . iRGD-LMC combined with UTMD achieves a significant thrombolytic effect in vitro .
    • 王晔晖
    • 摘要: 目的 探讨血肿穿刺置管引流术联合血肿腔内注射尿激酶治疗慢性硬膜下血肿的疗效.方法 共86例慢性硬膜下血肿患者行单侧或双侧、单孔或多孔血肿穿刺置管引流术,采取术中不冲洗、术后血肿腔内注射尿激酶(20×103 U/次、2次/d)的方法,计算治愈率,记录并发症(包括颅内出血和感染)发生率和复发率.结果 手术时间平均(0.60±0.16)h;注射尿激酶3d后脑组织均复位;平均随访(4.00±0.22)个月,治愈85例、治愈率为98.84%,复发1例、复发率为1.16%;无一例发生术后颅内出血、感染或需再次手术.结论 血肿穿刺置管引流术术中不冲洗、术后血肿腔内注射尿激酶治疗慢性硬膜下血肿,效果显著,复发率较低.
    • 农媛; 肖海; 陈奎; 张泰鹏; 李秀芬
    • 摘要: 目的 探讨尿激酶联合奥扎格雷钠治疗80岁以上高龄急性脑梗死患者的临床疗效及安全性.方法 选取2014年1月至2017年12月我院收治的80岁以上高龄急性脑梗死患者66例为研究对象,根据患者及家属意愿将纳入研究的老年患者分为溶栓治疗组(36例)和非溶栓治疗组(30例),采用随机数字表法将溶栓治疗组患者随机分为联合溶栓组(18例)和尿激酶溶栓组(18例).联合溶栓组患者采用尿激酶联合奥扎格雷钠治疗,尿激酶溶栓组患者采用尿激酶治疗,非溶栓治疗组患者采用奥扎格雷钠治疗.比较三组患者治疗24 h、3d、7d后的卒中量表(NIHSS)评分;比较三组患者治疗7d的出血事件发生率和病死率.结果 治疗方法与治疗时间对三组患者NIHSS评分的影响存在差异(P<0.05);治疗方法与治疗时间之间无交互作用(P>0.05).治疗7d后,三组患者的治疗有效率、显效率比较差异有统计学意义,表现为联合溶栓组>尿激酶溶栓组>非溶栓治疗组;联合溶栓组患者的显效率显著高于非溶栓治疗组,差异有统计学意义(P<0.05).治疗7d,三组患者的出血事件发生率及病死率比较,差异无统计学意义(P>0.05).结论 尿激酶联合奥扎格雷钠治疗80岁以上高龄急性脑梗死患者早期临床疗效显著,不会增加患者出血及死亡风险.
    • 阿丽米娜·阿文; 关丽娜; 虎晓梅; 穆玉明
    • 摘要: Purpose To observe the thrombolytic effect of different ultrasonic frequencies combined with urokinase-containing targeted microbubble contrast agent on rabbit femoral artery,to explore the main influencing factors,and to determine the potential indicators related to recurrent embolism in the microcirculation.Materials and Methods Unilateral femoral arterial thrombosis models were established in the selected 72 New Zealand white rabbits,which were randomly divided into 12 groups,6 rabbits in each group.This study was performed on an experimental combination of three factors and different levels,including different ultrasonic frequencies (1.6,2.2,2.8 MHz),different ultrasonic irradiation time (30 and 60 min),and different urokinase dose (3 and 6 mg).Thrombolysis with urokinase-containing targeted microbubble was performed under low frequency ultrasonic assisted irradiation,the recanalization status of blood vessels was observed,and recurrent embolism in the microcirculation was confirmed by HE staining.Furthermore,rabbit blood samples were collected,with indicators,including 6-keto-prostaglandin F1a (6-keto-PGF1a),Thromboxane B2 (TXB2),P/T ratio (6-keto-PGF1a/TXB2) and P-selectin (SP) being detected.Results All the vessels were recanalized.There was no occurrence of recurrent embolism in the group with ultrasonic frequency of 2.2 MHz,radiation time of 30 min,and urokinase dose of 3 mg.Rabbits' blood vessels were observed to be not completely recanalized in other groups,accompanied with different degree of recurrent embolism in the microcirculation.6-keto-PGF 1 a content of the rabbits in the group without recurrent embolism obviously increased after thrombolysis,and the difference was statistically significant (P<0.05).While,there was no statistical difference in other indicators (P>0.05).Conclsion The thrombolysis with ultrasound frequency of 2.2 MHz,irradiation time of 30 min,and urokinase dose of 3 mg could achieve complete recanalization of blood vessels.Under the certain conditions of ultrasonic frequency,irradiation time and urokinase dosage,thrombus can be effectively dissolved.However,there may be risk of recurrent embolism in the microcirculation during thrombolysis process.The increase of 6-keto-PGF 1a content has a certain effect on reducing the formation of recurrent embolism in the microcirculation.%目的 观察不同超声频率联合携尿激酶的靶向微泡造影剂对兔股动脉血栓的溶解作用,探讨影响溶栓作用的主要因素,寻找微循环再栓塞的相关指标.材料与方法 72只新西兰大白兔制作单侧股动脉血栓模型,按照完全随机分组方法分为12组,每组6只.根据超声频率(1.6、2.2、2.8 MHz)、超声照射时间(30、60 min)、尿激酶剂量(3、6mg)3因素不同水平进行实验组合.靶向微泡携带尿激酶在低频超声辅助照射下溶栓,观察血管的溶通情况,并通过HE染色证实有无微循环再栓塞.抽取兔血检测6-酮-前列腺素Fla(6-keto-PGF1a)、血栓素B2 (TXB2)、P/T比值(6-keto-PGF1a/TXB2)及P-选择素(SP)等指标.结果 超声频率2.2 MHz、超声照射时间30 min、尿激酶剂量3 mg组血管全部溶通且无微栓塞发生;其余各组均有未溶通或合并微循环再栓塞发生的情况.溶栓后无微栓塞组的兔6-keto-PGF1a含量明显升高,差异有统计学意义(P<0.05);而其他指标差异无统计学意义(P>0.05).结论 超声频率2.2 MHz、超声照射时间30 min、尿激酶低剂量3 mg的条件下溶栓可实现血管的完全溶通.超声频率、超声照射时间及尿激酶剂量一定时可有效溶解血栓,但在溶栓的过程中可能会发生微循环的再栓塞.6-keto-PGF1a含量的升高对降低微循环再栓塞具有一定作用.
    • 何大川; 雷雪; 董琼; 浦青; 杨丽霞; 高菡
    • 摘要: 目的 观察内科胸腔镜联合胸腔内注射尿激酶治疗结核包裹性胸膜炎的临床价值.方法 回顾性分析3年内106例结核包裹性胸膜炎患者分别经内科胸腔镜联合尿激酶治疗(A组)、尿激酶治疗(B组)、常规治疗(C组)3种不同治疗方法的临床疗效及安全性.结果 治疗后A组肺活量占预计值百分比、用力肺活量占预计值百分比、肺总量占预计值百分比优于B、C组(P<0.05),B组优于C组(P<0.05).A组显效率,有效率优于B、C组,B组优于C组(P<0.05).A组中2例患者术后并发气胸,其中1例右侧肺压缩90%均经引流治疗治愈.结论 内科胸腔镜联合胸腔内注射尿激酶治疗结核包裹性胸膜炎疗效较好,安全性高.
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号